Trial Profile
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 12 Mar 2018 Status changed to withdrawn prior to enrolment.
- 06 Sep 2010 New trial record